...
首页> 外文期刊>Critical care : >Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial (ISRCTN50308308).
【24h】

Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial (ISRCTN50308308).

机译:瑞芬太尼与基于标准催眠药的镇痛镇静剂与脑外伤的重症监护室患者的安全性和有效性:一项随机对照试验(ISRCTN50308308)。

获取原文
获取原文并翻译 | 示例

摘要

INTRODUCTION: This randomised, open-label, observational, multicentre, parallel group study assessed the safety and efficacy of analgesia-based sedation using remifentanil in the neuro-intensive care unit. METHODS: Patients aged 18-80 years admitted to the intensive care unit within the previous 24 hours, with acute brain injury or after neurosurgery, intubated, expected to require mechanical ventilation for 1-5 days and requiring daily downward titration of sedation for assessment of neurological function were studied. Patients received one of two treatment regimens. Regimen one consisted of analgesia-based sedation, in which remifentanil (initial rate 9 microg kg(-1) h(-1)) was titrated before the addition of a hypnotic agent (propofol [0.5 mg kg(-1) h(-1)] during days 1-3, midazolam [0.03 mg kg(-1) h(-1)] during days 4 and 5) (n = 84). Regimen two consisted of hypnotic-based sedation: hypnotic agent (propofol days 1-3; midazolam days 4 and 5) and fentanyl (n = 37) or morphine (n = 40) according to routine clinical practice. For each regimen, agents were titrated to achieve optimal sedation (Sedation-Agitation Scale score 1-3) and analgesia (Pain Intensity score 1-2). RESULTS: Overall, between-patient variability around the time of neurological assessment was statistically significantly smaller when using remifentanil (remifentanil 0.44 versus fentanyl 0.86 [P = 0.024] versus morphine 0.98 [P = 0.006]. Overall, mean neurological assessment times were significantly shorter when using remifentanil (remifentanil 0.41 hour versus fentanyl 0.71 hour [P = 0.001] versus morphine 0.82 hour [P < 0.001]). Patients receiving the remifentanil-based regimen were extubated significantly faster than those treated with morphine (1.0 hour versus 1.93 hour, P = 0.001) but there was no difference between remifentanil and fentanyl. Remifentanil was effective, well tolerated and provided comparable haemodynamic stability to that of the hypnotic-based regimen. Over three times as many users rated analgesia-based sedation with remifentanil as very good or excellent in facilitating assessment of neurological function compared with the hypnotic-based regimen. CONCLUSIONS: Analgesia-based sedation with remifentanil permitted significantly faster and more predictable awakening for neurological assessment. Analgesia-based sedation with remifentanil was very effective, well tolerated and had a similar adverse event and haemodynamic profile to those of hypnotic-based regimens when used in critically ill neuro-intensive care unit patients for up to 5 days.
机译:简介:这项随机,开放标签,观察性,多中心,平行小组研究评估了在神经重症监护病房中使用瑞芬太尼镇痛镇痛的安全性和有效性。方法:年龄在18-80岁的患者在过去24小时内入院重症监护病房,患有急性脑损伤或神经外科手术后,经插管,预计需要机械通气1-5天,并且每天需要进行镇静向下滴定以评估研究神经功能。患者接受了两种治疗方案之一。方案一是基于镇痛的镇静,其中瑞芬太尼(初始速率为9 microg kg(-1)h(-1))在添加催眠药(异丙酚[0.5 mg kg(-1)h(- 1)]在第1-3天中,咪达唑仑[0.03 mg kg(-1)h(-1)]在第4和5天中(n = 84)。方案二由基于催眠的镇静剂组成:催眠药(丙泊酚第1-3天;咪达唑仑第4和5天)和芬太尼(n = 37)或吗啡(n = 40),根据常规临床实践。对于每种方案,对药物进行滴定以达到最佳镇静效果(镇静-焦虑量表评分1-3)和镇痛(疼痛强度评分1-2)。结果:使用瑞芬太尼时,总体神经病学评估前后患者之间的差异具有统计学意义(瑞芬太尼0.44 vs芬太尼0.86 [P = 0.024] vs吗啡0.98 [P = 0.006])。总体而言,平均神经病学评估时间明显缩短当使用瑞芬太尼时(瑞芬太尼0.41小时vs芬太尼0.71小时[P = 0.001] vs吗啡0.82小时[P <0.001])。接受瑞芬太尼方案的患者拔管的时间明显比吗啡治疗的患者拔管快(1.0小时vs 1.93小时, P = 0.001),但瑞芬太尼和芬太尼之间没有差异;瑞芬太尼是有效的,耐受性良好的血液动力学稳定剂,与催眠药相比具有相当的血液动力学稳定性;三倍以上的使用者认为瑞芬太尼镇痛镇静效果非常好与基于催眠药的方案相比,在评估神经功能方面的优势或优势更强。瑞芬太尼以纳尔吉斯为基础的镇静作用,可使神经系统评估明显更快,更可预知。当用于重症神经重症监护病房患者长达5天时,瑞芬太尼以镇痛为基础的镇静非常有效,耐受性良好,并且与催眠药相比具有相似的不良事件和血液动力学特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号